{"id":5958,"date":"2025-09-17T09:30:49","date_gmt":"2025-09-17T07:30:49","guid":{"rendered":"https:\/\/www.m2olie.de\/?post_type=projects&p=5958"},"modified":"2025-11-04T11:52:47","modified_gmt":"2025-11-04T10:52:47","slug":"2nd-funding-period","status":"publish","type":"projects","link":"https:\/\/www.m2olie.de\/en\/projects\/2nd-funding-period\/","title":{"rendered":"2nd Funding Phase"},"content":{"rendered":"\n
\n
\n

2nd<\/sup> Funding Phase
<\/h4>\n\n\n\n
<\/div><\/div>
<\/div><\/div><\/div><\/div>\n\n\n\n

M\u00b2OLIE \u2013 The project. Mannheim Molecular Intervention Environment (2019\u20132024)<\/h3>\n\n\n\n

The treatment of patients with oligometastatic tumor disease in a closed-loop process was the focus of research activities in M\u00b2OLIE during the second funding phase. In the first funding phase, a wide variety of steps were successfully researched, including electronic patient education, novel imaging analyses, automated robot-assisted needle placement for biopsy and intervention, molecular classification of tumor entities using mass spectrometry, and convening an ad-hoc tumor board for therapy decision.

The goal of the research activities in the second funding phase was to integrate the previous individual steps into a seamless, time- and cost efficient process, which, by the end of the second funding phase, culminated in a clinical evaluation in tumor patients with individualized, minimally invasive therapy of all metastases.

The research was based on the close interconnection of the three joint projects: M\u00b2IBID<\/strong><\/a> with diagnostic and interventional imaging and molecular analysis, M\u00b2INT<\/strong><\/a> with automation and robotic assistance in biopsy and intervention, and M\u00b2DATA<\/strong><\/a> with the design of an M\u00b2OLIE-wide data supply process.
The complete M\u00b2OLIE closed-loop process will lead to a paradigm shift in the entire diagnostic and therapeutic treatment process for oncology patients.<\/p>\n\n\n\n

<\/div><\/div>
\n

<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

M\u00b2IBID<\/h4>\n\n\n\n

Molecular Innovative Imaging for Individualized Diagnostics
<\/h3>\n\n\n\n

The clear identification and characterization of therapy-relevant focal findings using innovative diagnostic methods forms the basis for minimally invasive therapy (including radionuclide therapy) for patients with oligometastases in the closed-loop process of M\u00b2OLIE. It also allows prediction of the expected response to therapy and early identification of patients who do not respond to a particular therapy (non-responders).<\/p>\n\n\n\n

The aim of the M\u00b2IBID joint project was to investigate these basic requirements for determining effective therapy in the sense of \u201cprecision medicine.\u201d The techniques of diagnostic and interventional imaging and molecular mass spectrometry (MS) bioanalytics were to be more deeply integrated and clinically evaluated. The innovative research goal was to ideally combine all this information to explore novel tumor characterizations using radiomics approaches and machine learning techniques that improve patient-specific intervention. The M\u00b2IBID joint project was carried out on an interdisciplinary basis within the framework of the four subprojects \u201cM\u00b2IP,\u201d \u201cM\u00b2OT\u00b2AN,\u201d \u201cSIM\u00b2BA,\u201d and \u201cM\u00b2KoRaMo.\u201d<\/p>\n\n\n\n

\n

Integration of imaging, molecular bioanalytics, and AI-supported procedures for personalized, and minimally invasive therapy.
<\/p>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n
Results from the second funding phase<\/strong><\/h6>\n\n\n\n